110 related articles for article (PubMed ID: 17084082)
1. The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain.
Giblin GM; Bit RA; Brown SH; Chaignot HM; Chowdhury A; Chessell IP; Clayton NM; Coleman T; Hall A; Hammond B; Hurst DN; Michel AD; Naylor A; Novelli R; Scoccitti T; Spalding D; Tang SP; Wilson AW; Wilson R
Bioorg Med Chem Lett; 2007 Jan; 17(2):385-9. PubMed ID: 17084082
[TBL] [Abstract][Full Text] [Related]
2. Discovery of GSK345931A: An EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain.
Hall A; Brown SH; Budd C; Clayton NM; Giblin GM; Goldsmith P; Hayhow TG; Hurst DN; Naylor A; Anthony Rawlings D; Scoccitti T; Wilson AW; Winchester WJ
Bioorg Med Chem Lett; 2009 Jan; 19(2):497-501. PubMed ID: 19036582
[TBL] [Abstract][Full Text] [Related]
3. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis.
Clark P; Rowland SE; Denis D; Mathieu MC; Stocco R; Poirier H; Burch J; Han Y; Audoly L; Therien AG; Xu D
J Pharmacol Exp Ther; 2008 May; 325(2):425-34. PubMed ID: 18287210
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.
Colucci J; Boyd M; Berthelette C; Chiasson JF; Wang Z; Ducharme Y; Friesen R; Wrona M; Levesque JF; Denis D; Mathieu MC; Stocco R; Therien AG; Clarke P; Rowland S; Xu D; Han Y
Bioorg Med Chem Lett; 2010 Jun; 20(12):3760-3. PubMed ID: 20471829
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of 1,5-biaryl pyrroles as EP1 receptor antagonists.
Hall A; Atkinson S; Brown SH; Chessell IP; Chowdhury A; Clayton NM; Coleman T; Giblin GM; Gleave RJ; Hammond B; Healy MP; Johnson MR; Michel AD; Naylor A; Novelli R; Spalding DJ; Tang SP
Bioorg Med Chem Lett; 2006 Jul; 16(14):3657-62. PubMed ID: 16697196
[TBL] [Abstract][Full Text] [Related]
6. Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.
Hall A; Billinton A; Brown SH; Chowdhury A; Clayton NM; Giblin GM; Gibson M; Goldsmith PA; Hurst DN; Naylor A; Peet CF; Scoccitti T; Wilson AW; Winchester W
Bioorg Med Chem Lett; 2009 May; 19(9):2599-603. PubMed ID: 19332369
[TBL] [Abstract][Full Text] [Related]
7. EP1 antagonists for the treatment of inflammatory pain.
Hall A; Billinton A; Giblin GM
Curr Opin Drug Discov Devel; 2007 Sep; 10(5):597-612. PubMed ID: 17786859
[TBL] [Abstract][Full Text] [Related]
8. Discovery of heteroaryl sulfonamides as new EP1 receptor selective antagonists.
Naganawa A; Matsui T; Saito T; Ima M; Tatsumi T; Yamamoto S; Murota M; Yamamoto H; Maruyama T; Ohuchida S; Nakai H; Kondo K; Toda M
Bioorg Med Chem; 2006 Oct; 14(19):6628-39. PubMed ID: 16784865
[TBL] [Abstract][Full Text] [Related]
9. Differential modulation of inflammatory pain by a selective estrogen receptor beta agonist.
Gardell LR; Hyldtoft L; Del Tredici AL; Andersen CB; Fairbairn LC; Lund BW; Gustafsson M; Brann MR; Olsson R; Piu F
Eur J Pharmacol; 2008 Sep; 592(1-3):158-9. PubMed ID: 18644363
[TBL] [Abstract][Full Text] [Related]
10. 1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists. Structure-activity relationships of 6-substituted and 5,6-disubstituted benzoic acid derivatives.
Hall A; Brown SH; Chessell IP; Chowdhury A; Clayton NM; Coleman T; Giblin GM; Hammond B; Healy MP; Johnson MR; Metcalf A; Michel AD; Naylor A; Novelli R; Spalding DJ; Sweeting J; Winyard L
Bioorg Med Chem Lett; 2007 Feb; 17(4):916-20. PubMed ID: 17175160
[TBL] [Abstract][Full Text] [Related]
11. Potent bradykinin B1 receptor antagonists: 4-substituted phenyl cyclohexanes.
Su DS; Lim JL; Markowitz MK; Wan BL; Murphy KL; Reiss DR; Harrell CM; O'Malley SS; Ransom RW; Chang RS; Pettibone DJ; Tang C; Prueksaritanont T; Freidinger RM; Bock MG
Bioorg Med Chem Lett; 2007 Jun; 17(11):3006-9. PubMed ID: 17428657
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.
Giblin GM; O'Shaughnessy CT; Naylor A; Mitchell WL; Eatherton AJ; Slingsby BP; Rawlings DA; Goldsmith P; Brown AJ; Haslam CP; Clayton NM; Wilson AW; Chessell IP; Wittington AR; Green R
J Med Chem; 2007 May; 50(11):2597-600. PubMed ID: 17477516
[TBL] [Abstract][Full Text] [Related]
13. 2,3-diaminopyridine bradykinin B1 receptor antagonists.
Kuduk SD; Ng C; Feng DM; Wai JM; Chang RS; Harrell CM; Murphy KL; Ransom RW; Reiss D; Ivarsson M; Mason G; Boyce S; Tang C; Prueksaritanont T; Freidinger RM; Pettibone DJ; Bock MG
J Med Chem; 2004 Dec; 47(26):6439-42. PubMed ID: 15588075
[TBL] [Abstract][Full Text] [Related]
14. 1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists: Structure-activity relationships of 4- and 5-substituted benzoic acid derivatives.
Hall A; Brown SH; Chessell IP; Chowdhury A; Clayton NM; Coleman T; Giblin GM; Hammond B; Healy MP; Johnson MR; Metcalf A; Michel AD; Naylor A; Novelli R; Spalding DJ; Sweeting J
Bioorg Med Chem Lett; 2007 Feb; 17(3):732-5. PubMed ID: 17098427
[TBL] [Abstract][Full Text] [Related]
15. The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.
Blouin M; Han Y; Burch J; Farand J; Mellon C; Gaudreault M; Wrona M; Lévesque JF; Denis D; Mathieu MC; Stocco R; Vigneault E; Therien A; Clark P; Rowland S; Xu D; O'Neill G; Ducharme Y; Friesen R
J Med Chem; 2010 Mar; 53(5):2227-38. PubMed ID: 20163116
[TBL] [Abstract][Full Text] [Related]
16. Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists.
Wood MR; Schirripa KM; Kim JJ; Wan BL; Murphy KL; Ransom RW; Chang RS; Tang C; Prueksaritanont T; Detwiler TJ; Hettrick LA; Landis ER; Leonard YM; Krueger JA; Lewis SD; Pettibone DJ; Freidinger RM; Bock MG
J Med Chem; 2006 Feb; 49(4):1231-4. PubMed ID: 16480259
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel series of nonacidic benzofuran EP1 receptor antagonists.
Allan AC; Billinton A; Brown SH; Chowdhury A; Eatherton AJ; Fieldhouse C; Giblin GM; Goldsmith P; Hall A; Hurst DN; Naylor A; Rawlings DA; Sime M; Scoccitti T; Theobald PJ
Bioorg Med Chem Lett; 2011 Jul; 21(14):4343-8. PubMed ID: 21676612
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects.
Ushiyama S; Yamada T; Murakami Y; Kumakura S; Inoue S; Suzuki K; Nakao A; Kawara A; Kimura T
Eur J Pharmacol; 2008 Jan; 578(1):76-86. PubMed ID: 17920584
[TBL] [Abstract][Full Text] [Related]
19. Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy.
Hall A; Billinton A; Brown SH; Clayton NM; Chowdhury A; Giblin GM; Goldsmith P; Hayhow TG; Hurst DN; Kilford IR; Naylor A; Passingham B; Winyard L
Bioorg Med Chem Lett; 2008 Jun; 18(11):3392-9. PubMed ID: 18462938
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel pyrazole acid antagonists for the EP1 receptor.
McKeown SC; Hall A; Giblin GM; Lorthioir O; Blunt R; Lewell XQ; Wilson RJ; Brown SH; Chowdhury A; Coleman T; Watson SP; Chessell IP; Pipe A; Clayton N; Goldsmith P
Bioorg Med Chem Lett; 2006 Sep; 16(18):4767-71. PubMed ID: 16843659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
